18-40 years old | Female
This vaccine (mRNA-1647) is designed to protect against cytomegalovirus (CMV) infection. This trial is for individuals who are CMV seronegative (never had CMV).
This vaccine (mRNA-1647) is designed to protect against cytomegalovirus (CMV) infection. This trial is for individuals who are CMV seronegative (never had CMV).
Up to 14 visits over ~30 months
Participants are paid for diary compliance and for time and travel associated with completion of study visits